Apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer via the Akt/β-catenin pathway.

Bin WeiYuanyuan WangJiawei WangXiaomin CaiLingyan XuJingjing WuYing WangWen LiuYan-Hong GuWenjie GuoQiang Xu

Published in: Cancer cell international (2020)

Our study indicates that apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer by deactivating the Akt/β-catenin pathway. These findings provide a theoretical foundation for using apatinib as an effective therapeutic drug for esophageal cancer.

Keyphrases

signaling pathway
poor prognosis
cell proliferation
long non coding rna
adverse drug
drug induced